Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01917006 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT01917006 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 59 participants.
The verdict
NCT01917006, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of OnabotulinumtoxinA for the treatment of premature ejaculation (PE) in male participants.
Interventions
- DRUG Normal Saline
- DRUG OnabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2013-08-07 |
| Est. Completion | 2017-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01917006
The ClinicalTrials.gov registry entry for NCT01917006 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT01917006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01917006 about?
NCT01917006 is a clinical study titled "A Safety and Efficacy Study of OnabotulinumtoxinA in Premature Ejaculation". This is a safety and efficacy study of OnabotulinumtoxinA for the treatment of premature ejaculation (PE) in male participants.
What is the current status of trial NCT01917006?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2013-08-07. Estimated completion is 2017-08-15.
What interventions are being tested in trial NCT01917006?
The interventions under investigation include: Normal Saline (DRUG), OnabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT01917006?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.